In8bio (INAB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

INAB In8bio

Watchlist

0.257
-0.013-4.78%

Close Oct 1 16:00 ET

0.311
+0.054+20.96%

Pre 04:17 ET

12.03MMarket Cap-313P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | IN8bio, Inc. - Units Sold at $0.395 per Unit
ReutersOct 1 08:01 ET
Express News | IN8bio, Inc. - Net Proceeds Expected to Fund Operating Plan Into 2026
ReutersOct 1 08:01 ET
Express News | IN8bio Announces Pricing of $12.4 Million Private Placement
ReutersOct 1 08:00 ET
IN8bio Revises Executive Compensation and Severance Terms
TipRanksSep 7 10:43 ET
IN8bio Shares Are Trading Lower Amid a Possible Selloff. The Company Announced It Will Focus on Generating Robust Clinical Data From INB-100, the Ongoing Investigator-sponsored Phase 1 Clinical Trial of Acute Myeloid Leukemia and Said It Will Preserve...
BenzingaSep 5 11:37 ET
IN8bio Cuts Staff and Pipeline to Focus on AML Cell Therapy
Yahoo FinanceSep 5 08:33 ET

Comments

Trytosaveabit

20 minutes ago

PP filed 8K last evening

$In8bio (INAB.US)$ On September 30, 2024, In8bio, Inc. announced the entry into a Securities Purchase Agreement with certain investors for a private placement. The agreement involves the sale of approximately 25.76 million shares of common stock, 5.65 million pre-funded warrants, and 31.41 million Series C warrants, generating initial gross proceeds of around $12.4 million. This capital is intended to support the company's operations into 2026. The pre-funded warrants have...

$In8bio (INAB.US)$ Luckily didnt hold this…

Trytosaveabit

Sep 4 15:07

A bit more

$In8bio (INAB.US)$ IN8bio Announces Clinical Pipeline Prioritization To Focus On INB-100 For Acute Myeloid Leukemia And A Workforce Reduction Of ~49%; Suspending Enrollment Of Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed GBM; Will Continue To Monitor Patients For Long-Term Remissions And Overall Survival In Both INB-400 And INB-200 At UAB
Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additiona...